Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3350509
Max Phase: Preclinical
Molecular Formula: C27H47IN7O15P3
Molecular Weight: 929.53
Molecule Type: Small molecule
Associated Items:
ID: ALA3350509
Max Phase: Preclinical
Molecular Formula: C27H47IN7O15P3
Molecular Weight: 929.53
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CN(CCCCCCN(C)c1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O)C(=O)CCCCCCNC(=O)CI
Standard InChI: InChI=1S/C27H47IN7O15P3/c1-33(21(37)11-7-3-4-8-12-29-20(36)15-28)13-9-5-6-10-14-34(2)25-22-26(31-17-30-25)35(18-32-22)27-24(39)23(38)19(48-27)16-47-52(43,44)50-53(45,46)49-51(40,41)42/h17-19,23-24,27,38-39H,3-16H2,1-2H3,(H,29,36)(H,43,44)(H,45,46)(H2,40,41,42)/t19-,23-,24-,27-/m1/s1
Standard InChI Key: QJHWQOZXVAOVBK-GVDONAMHSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 929.53 | Molecular Weight (Monoisotopic): 929.1388 | AlogP: 1.75 | #Rotatable Bonds: 24 |
Polar Surface Area: 305.76 | Molecular Species: ACID | HBA: 16 | HBD: 7 |
#RO5 Violations: 3 | HBA (Lipinski): 22 | HBD (Lipinski): 7 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 0.90 | CX Basic pKa: 4.60 | CX LogP: -1.96 | CX LogD: -7.12 |
Aromatic Rings: 2 | Heavy Atoms: 53 | QED Weighted: 0.03 | Np Likeness Score: 0.26 |
1. Hampton A, Picker D, Nealy KA, Maeda M.. (1982) Use of adenine nucleotide derivatives to assess the potential of exo-active-site-directed reagents as species- or isozyme-specific enzyme inactivators. 4. Interactions of adenosine 5'-triphosphate derivatives with adenylate kinases from Escherichia coli and rat tissues., 25 (4): [PMID:6279845] [10.1021/jm00346a010] |
2. Hampton A, Patel AD, Chawla RR, Kappler F, Hai TT.. (1982) Use of adenine nucleotide derivatives to assess the potential of exo-active-site-directed reagents as species- or isozyme-specific enzyme inactivators. 5. Interactions of adenosine 5'-triphosphate derivatives with rat pyruvate kinases, Escherichia coli thymidine kinase, and yeast and rat hexokinases., 25 (4): [PMID:7040662] [10.1021/jm00346a011] |
Source(1):